Product Description
An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities
Mechanisms of Action: TIM3 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-184034 |
JapicCTI-184034 | P2 |
Active |
Oncology Solid Tumor Unspecified |
2023-07-01 |
|||
jRCT2080223976 |
jRCT2080223976 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2023-07-01 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/21/2022 |
News Article |
TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 |
|
08/06/2020 |
News Article |
Five Prime Therapeutics Reports Second Quarter 2020 Results |
|
05/07/2020 |
News Article |
Five Prime Therapeutics Reports First Quarter 2020 Results |
|
02/27/2020 |
News Article |
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results |